导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 6.17% | 1014/4773 |
| 近一周 | -2.80% | 3130/5462 |
| 近一月 | -5.01% | 2974/5421 |
| 近一季 | -8.49% | 2820/5209 |
| 近半年 | -3.52% | 2231/4920 |
| 近一年 | 13.25% | 790/4366 |
| 近两年 | 86.56% | 726/2954 |
| 近三年 | 52.52% | 509/2253 |
| 成立以来 | 77.23% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.48% 919/4961 |
22.03% 1141/5312 |
- - |
- - |
| 2025 | 37.91% 880/4813 |
4.10% 993/3635 |
2.62% 1461/4076 |
26.82% 1332/4524 |
1.80% 1207/4813 |
| 2024 | 10.76% 1376/3463 |
-1.91% 1296/2808 |
-0.29% 727/3014 |
12.86% 2283/3129 |
0.34% 1226/3463 |
| 2023 | -9.18% 1122/2656 |
7.13% 601/2280 |
-4.41% 1164/2385 |
-6.02% 1414/2515 |
-5.64% 1436/2655 |
| 2022 | -19.89% 911/2207 |
-13.29% 726/1919 |
5.02% 949/2016 |
-11.11% 494/2113 |
-1.04% 1672/2208 |
| 2021 | 17.98% 219/1822 |
0.05% 320/1255 |
14.57% 250/1330 |
5.29% 282/1466 |
-2.25% 1407/1822 |
| 2020 | 47.18% 199/1250 |
0.48% 162/1028 |
18.91% 318/1067 |
14.71% 264/1164 |
7.39% 713/1184 |
| 2019 | 30.63% 480/1092 |
28.63% 299/739 |
-8.15% 579/788 |
3.42% 252/850 |
6.92% 517/918 |
| 2018 | -20.33% 190/834 |
- - |
-11.32% 358/631 |
-7.87% 471/660 |
-10.64% 211/682 |
| 2017 | 2.90% 436/714 |
- - |
- - |
- - |
- - |
| 2016 | -18.17% 409/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 天弘中证500指数增强A VS. 长安沪深300非周期A(740101) |